HIV/AIDS Therapy

Company updates development of fixed-dose regimen of Truvada and Sustiva

Published in Drug Week, September 9th, 2005

Gilead Sciences, Inc., (GILD) announced that bioequivalence results from its second formulation of the fixed-dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Bristol-Myers Squibb's Sustiva (efavirenz) for the treatment of HIV did not demonstrate bioequivalence to the individual products dosed separately.

The company is proceeding with the evaluation of up to three new formulations, developed based on bilayer technology. This bilayer technology involves coformulation of Truvada and Sustiva as individually formulated layers combined together in one tablet. Gilead will initiate the bioequivalence studies in humans and stability studies of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-09-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry